Trial · NCT05130450
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Change From Baseline in Fasting TG at 6 Months (Average of Weeks 23, 25, and 27) Compared to Baseline | Baseline and 6 months | |
| Secondary | Percent Change From Baseline in Fasting TG at 12 Months (Average of Weeks 51 and 53) at 24 Months (Average of Week 103 and Week 105) and 36 Months (Average of Week 155 and Week 157) | Baseline and 36 months | |
| Secondary | Percentage of Participants Who Achieve ≥ 40% Reduction in Fasting TG From Baseline at 6 Months | At 6 months | |
| Secondary | Percentage of Participants Who Achieve ≥ 40% Reduction in Fasting TG From Baseline at 12, 24, 36 Months | At 12, 24, 36 months | |
| Secondary | Percent Change in Fasting apoC-III from Baseline at Month 6 | Baseline and 6 months | |
| Secondary | Percent Change in Fasting apoC-III from Month 12, 24, 36 | At 12, 24, 36 months | |
| Secondary | Percent Change From Baseline in Fasting Apolipoprotein 48 (apoB48) at 6 Months | At 6 months | |
| Secondary | Percent Change From Baseline in Fasting apoB48 at 12, 24, 36 Months | At 12, 24, 36 months | |
| Secondary | Percent Change in Fasting non-HDL-C from Baseline at Month 6 | Baseline and 6 months | |
| Secondary | Percent Change in Fasting non-HDL-C from Months 12, 24, 36 | At 12, 24, 36 months | |
| Secondary | Percentage of Participants Who Achieve Fasting TG ≤ 880 milligrams per deciliter (mg/dL) at 6 Months | At 6 months | |
| Secondary | Percentage of Participants Who Achieve Fasting TG ≤ 880 mg/dL at 12, 24, 36 months | At 12, 24, 36 months | |
| Secondary | Adjudicated Acute Pancreatitis Event Rate During the Treatment Period in Participants With ≥ 2 Events of Adjudicated Acute Pancreatitis in 5 Years Prior to Treatment With Study Drug in the Index Study | Week 1 through Week 157 | |
| Secondary | Adjudicated Acute Pancreatitis Event Rate During the Treatment Period | Week 1 through Weeks 53, 105, or 157 | |
| Secondary | Adjudicated Acute Pancreatitis Event Rate During the Treatment Period in Patients with a Prior History of Pancreatitis within 10 Years Prior to Screening in the Index Study | Week 1 through Weeks 53, 105, or 157 | |
| Secondary | Percentage of Participants Who Achieve ≥ 70% Reduction in Fasting TG From Baseline at 6 Months | At 6 months | |
| Secondary | Percentage of Participants Who Achieve ≥ 70% Reduction in Fasting TG From Baseline at 12, 24, 36 Months | At 12, 24, 36 months | |
| Secondary | Percentage of Participants Who Achieve Fasting TG ≤ 500 mg/dL at 6 Months | At 6 months | |
| Secondary | Percentage of Participants Who Achieve Fasting TG ≤ 500 mg/dL at 12, 24, 36 Months | At 12, 24, 36 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05130450/registered